WEBULL
WebtradeDownload

CPBIO Holding (SEHK:3839) Stock Faces Revenue Slide Despite Firmer Margins

Simply Wall St · 1d ago

CPBIO Holding stock closed at HK$8.76 on 12 August after a choppy few weeks, with the share price drifting down over the past month even as fresh earnings hit the market. The headline from Q2 is clear. Revenue reached US$112.4m while net income from ongoing operations came in at US$3.8m, pointing to pressure on profitability despite a solid top line.

The mood today looks more cautious than euphoric. Investors appear to be focusing on the squeeze between sales and earnings, testing how much of the recent valuation story around CPBIO Holding still holds.

Is CPBIO Holding now priced as a genuine bargain, or just wearing a value label because earnings have come under pressure? Compare the current share price against a full discounted cash flow view on our valuation analysis for CPBIO Holding

Q2 2026 Earnings Summary

  • Revenue, Q2 2026 vs. Q2 2025: US$112.4m vs. US$158.3m (lower year on year)
  • Net Income from Ongoing Operations, Q2 2026 vs. Q2 2025: US$3.8m vs. US$9.4m (lower year on year)
  • Basic EPS, Trailing Twelve Months (TTM) to Q2 2026 vs. TTM to Q2 2025: US$0.096 vs. US$0.104 (TTM EPS slightly lower year on year)
  • Net Profit Margin, Trailing Twelve Months (TTM) to Q2 2026 vs. TTM to Q2 2025: 5.8% vs. 5.0% (margin higher year on year)

Tired of scrolling through dense earnings reports and spreadsheets? See CPBIO Holding's full financial picture, including a clear visual view of its recent earnings trend, in our company report for CPBIO Holding..

SEHK:3839 Trailing 12-Month Earnings & Revenue History as at Aug 2026
SEHK:3839 Trailing 12-Month Earnings & Revenue History as at Aug 2026

CPBIO Holding bull case leans on margin resilience

For a bullish view on CPBIO Holding, the key support is that profitability has not broken down even with softer activity. Trailing net profit margin is 5.8%, higher than the 5.0% level a year earlier, despite revenue for Q2 falling from US$158.3m to US$112.4m and quarterly net income easing to US$3.8m. That points to some cost discipline or mix support in the core operations. For investors who see the animal health platform as the long term anchor, this margin trend can be read as the business holding its ground rather than sliding.

CPBIO Holding bear case focuses on revenue pressure

Bears will likely point first to the top line. Q2 revenue of US$112.4m is well below the prior US$158.3m, and net income from ongoing operations is also lower at US$3.8m versus US$9.4m. Basic EPS on a trailing basis has edged down from US$0.104 to US$0.096. Short term share performance also reflects some of this caution, with the stock down about 5% over 7 days and 8% over 30 days. That combination keeps questions alive around growth momentum across both animal health and the more cyclical Investment segment.

With CPBIO Holding reporting negative earnings over the most recent 12 months while still trading on an 11.6x P/E, many investors are asking how secure the balance sheet really is. Check the full solvency and liquidity breakdown in our financial health analysis of CPBIO Holding stock.

Stay Ahead With Simply Wall St

If the recent revenue pressure and margin resilience at CPBIO Holding has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a price that fits your plan. Once you hold CPBIO Holding or other stocks, use the Portfolio Command Center to cut through noise and focus on the most important developments for your positions. For a broader view on what other investors are seeing in CPBIO Holding and the wider market, turn to the Community and compare perspectives. This way you can spot potential catalysts and risks earlier and stay a step ahead of the market.

Seeking Alternatives Beyond CPBIO Holding?

Fresh stock ideas move fast. Some are building quiet breakout momentum, others are dropping into attractive zones that may not stay under the radar for long, so act now.

  • Spot potential breakout candidates with stronger cash generation and balance sheets by scanning our curated list of solid balance sheet and fundamentals stocks (422 results) before the crowd closes in on the same opportunities.
  • Pursue higher income potential by focusing on companies screened for stability alongside meaningful yields using our hand picked 438 dividend fortresses while those payouts still look appealing.
  • Chase early momentum in companies riding the AI build out by reviewing carefully filtered 57 AI infrastructure stocks while these trends remain under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.